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Interleukin 1 modulates growth of human renal carcinoma cells in vitro
I Koch, H Depenbrock, S Danhauser-Riedl, JW Rastetter and A-R Hanauske
Division ofHematology and Oncology, Klinikum rechts der Isar der Technischen Universitat Muinchen, Ismaninger Str. 22, 81675
Munich, Germany.
Summary We have investigated the influence of interleukin I (IL-1) on growth of human renal carcinoma
cells in vitro. Using a capillary soft-agar cloning system, 18% of freshly explanted renal carcinomas were
stimulated to grow by IL-1 and 4% were inhibited. Subsequent experiments with established renal cancer cell
lines demonstrated that two out of four cell lines (Caki-2, A-498) were sensitive to IL-1. ['H]Thymidine
incorporation as well as monolayer growth was enhanced in Caki-2 cells in the presence of high (10%) and
low (1%) serum concentrations. Although clonogenic growth of A-498 cells was stimulated by IL-1, overall
[3H]thymidine incorporation and monolayer proliferation were decreased. Using radioligand experiments, 250
cell-surface receptors of high affinity (KD 4.5 x 10-" M) and 2500 receptors of low affinity (KD 1.3 x 10-9M)
were detected on A-498 cells. IL-1 binding was reduced under the influence of IL-1. Competition experiments
with inhibiting antibodies against IL-I receptor type I and type II revealed that signal transduction was
performed via type I receptors. After cross-linking to IL-1, receptor type I was immunoprecipitated using
anti-IL-1 antibodies. We hypothesise that, since IL-1 modulates in vitro growth of a subgroup of human renal
cancer cells, interference with its mechanism of action may be of potential value in order to modulate tumour
proliferation.
Keywords: interleukin 1; tumour cell proliferation; IL-1 receptor expression
Although IL-1 was first characterised as a haematopoietic
growth factor, it is now known to have biological effects in
many different cell types. Two different peptides without
marked difference in their biological activity, but with only
26% homology at the protein level, each of a molecular mass
of 17 kDa, are termed IL-la and IL-1p. Binding studies with
lymphocytes revealed high- (KD 5 x 10-11 M) and low- (KD
5 x 10-9M) affinity binding sites (Mizel et al., 1987;
McMahan et al., 1991). Two different receptors of 80 kDa
(type I) and 68 kDa (type II) have been detected by protein
analysis, the former mainly, but not exclusively, on T cells
and fibroblasts and the latter on B cells. cDNAs of both
receptors have been cloned and expressed (Solari, 1990; Ruhl
et al., 1992). High- and low-affinity binding sites for both
IL-lo and IL-1p may be co-located on one or both receptors
(Solari, 1990; Slack et al., 1993). Both IL-1 receptors contain
an immunoglobulin-like domain which binds IL-1, but the
overall homology of this region in type I and type II recep-
tors is only 28% (McMahan et al., 1991; Ruhl et al., 1992).
It has been reported that signal transduction is exclusively
mediated through receptor type I, which has an intracellular
domain of 217 amino acids (Sims et al., 1993). Despite
lacking homology to any known protein, this intracellular
domain is sufficiently long to encode for yet unidentified
enzymatic function. In contrast, IL-1 receptor type II has a
short intracellular domain of only 29 amino acids and might
trap IL-1 without subsequent signal transduction, thus
regulating IL-i-induced biological responses (McMahan et
al., 1991; Colotta et al., 1993).
While IL-I is a known growth factor for T and B cells, its
potential significance for tumour cell proliferation is less
clear. Some tumours appear to be stimulated, but growth of
others is inhibited in vitro (Michiel and Oppenheim, 1992).
Binding of tumour cells to endothelial cells in vitro and to
blood vessel endothelium in vivo is enhanced under the
influence of IL-1 (Giavazzi et al., 1990; Lauri et al., 1990).
Thus, IL-1 may play a role in the formation of metastases in
vivo. However, it is presently unclear how growth of tumour
cells is modulated by IL-1 and which factors control the
cellular response pattern to IL-1.
IL-l is currently undergoing clinical investigation for use
in cancer patients. It is therefore of interest to study the
effects of IL-I on tumour cell proliferation. The purpose of
the present study was to evaluate the effects of IL-la and
IL-1p on freshly explanted human tumour cells and to re-
produce the results using human renal carcinoma cell lines in
order to scrutinise IL-1 receptor expression and IL-1-
mediated cellular responses in human cancer cells.
Materials and methods
Materials
Human recombinant IL-lao was a generous gift from
Hoffman LaRoche (Nutley, NJ, USA). [3H]Thymidine, IL-1p
and ['25I]IL-la were purchased from Amersham-Buchler
(Braunschweig, Germany). Antibodies against IL-lla and
IL-1p and against IL-1 receptor types I and II were from
Genzyme (Cambridge, MA, USA). Protein G Sepharose and
disuccinimidylsuberate (DSS) were from Pierce (Rockford,
IL, USA). Glassfibre filters were from Whatman (Clifton,
NJ, USA). HEPES buffer solution as well as all tissue culture
media, sera and additives were from Gibco-BRL (Eggenstein,
Germany).
Cell lines and cell culture media
Human renal cancer cell lines were purchased from the
American Type Culture Collection (Rockville, MD, USA)
and cultured in the following media:
A-498: modified Eagle's medium containing 10% fetal calf
serum (FCS), non-essential amino acids and 1 mM sodium
pyruvate;
Caki-l: McCoy's 5A medium containing 10% FCS;
Caki-2: McCoy's 5A medium containing 10% FCS;
ACHN: modified Eagle's medium containing 10% FCS
and non-essential amino acids.
Soft-agar cloning
Single-cell suspensions of solid human tumours were
prepared mechanically; cultured cells were harvested with
0.25% trypsin/l mM EDTA. Cells were seeded in 100 tl
capillaries (six capillaries for each concentration) at a density
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of 40 000-62 000 cells per capillary in CMRL 1066 (cells
from solid tumours) or 8000-20 000 cells ml-' in the tissue
culture medium (cell lines) with 0.3% agar with or without
increasing concentrations of IL-la or IL-1p. Concentrations
of FCS were as indicated in the text or legends to figures for
different experiments. After incubation at 37°C for 3 weeks,
colonies were examined and counted by light microscopy.
Monolayer assay
Approximately 2 x 104 cells were seeded in 24-well tissue
culture plates in the tissue culture medium with concentra-
tions of FCS as indicated with or without increasing con-
centrations of IL-la or IL-1p. After various periods of
incubation, cells were harvested with 0.25% trypsin/I mM
EDTA and counted.
[3H]Thymidine incorporation
Cells were seeded in 96-well tissue culture plates (1-5 x 103
cells per well) in medium with concentrations of FCS as
indicated. After 3 days, the medium was changed and IL-la
or IL-1p was added. Incubation periods were 24, 48, 72, or
96 h. [3H]Thymidine (0.75 tCi) was added 4 h before the end
of the incubation period. Thereafter, cells were washed and
harvested onto micro-glassfibre filters and the incorporated
radioactivity was determined by P-scintillation counting.
Enzyme-linked immunosorbent assay (ELISA)
The conditioned media of the cell lines were studied for
IL-la and IL-lp using the Biotrak ELISA system (Amer-
sham-Buchler, Braunschweig, Germany) as described by the
manufacturer.
IL-I radioreceptor assay
Cells were seeded in 24-well plates with or without IL-la.
When subconfluent, cells were washed once with binding
medium pH 3.0 for 30 s in order to remove bound ligand and
neutralised twice with binding medium (tissue culture
medium with 20 mM HEPES, pH 7.0). ['25I]IL-1I was added
at the indicated concentrations for direct binding assays and
at a concentration of 80 pM and with increasing concentra-
tions of unlabelled IL-Ia for competition assays. Plates were
incubated at 4°C for 3 h, then washed four times with
phosphate-buffered saline (PBS) (140 mM sodium chloride,
30 mM potassium chloride, 6.5 mM disodium hydrogen phos-
phate, 1.2 mM potassium dihydrogen phosphate pH 7.2).
Cells were lysed with 1 ml of 0.5% sodium dodecyl sulphate
(SDS) and radioactivity was determined in a gamma-counter.
Ligand- receptor cross-linking and immunoprecipitation
Cells (confluency 90%) were incubated with 5 ngml' IL-lp
for 3 h. at 4°C and washed four times with ice-cold PBS.
Cross-linking was performed with DSS (1 mgml-') in PBS
for 1 h at 4°C. Cells were washed twice with PBS, harvested
wtih 20 mM EDTA in PBS and lysed with 1% Triton X-100
in PBS. Cell debris was removed by centrifugation. Lysates
were diluted to a concentration of 0.5 mg ml-' protein with
NET buffer (50 mM Tris-HCI pH 8.0, 150 mM sodium
chloride, 0.1% Nonidet-P40, 1 mM EDTA, 0.25% gelatin)
and incubated with antibodies against IL-l at a concentra-
tion of 10 fg ml-' for 1 h at 4C. Protein G-cellulose was
added and the incubation was continued for 1 h at 4°C.
Unbound proteins were removed by five washes with NET
buffer. SDS-polyacrylamide gel loading buffer (25 mM
Tris-HCI pH 6.8, 2% SDS, 1% 2-mercaptoethanol, 10%
glycerin, 0.25% bromophenol blue) was added to the final
protein G-cellulose pellet and samples were boiled for 5 min
and cooled on ice. After electrophoresis on 10% acrylamide
gels, proteins were blotted onto nitrocellulose filters (Laem-
mli, 1970). Filters were subsequently incubated with the
antibody against IL-lp and a horseradish peroxidase-coupled
anti-mouse antibody and stained with diaminobenzidine.
For direct immunoprecipitations of the receptor, cell
lysates were incubated with antibodies against IL-1 receptor
type I or II without prior cross-linking. In this case, Western
blots were treated with anti-receptor antibodies.
Results
Freshly explanted human tumour cells were cloned in soft
agar with or without IL-la or IL-ip (0.1-l00ngmlV') to
investigate the influence of IL-l on the clonogenic growth of
human tumour cells (Buick and Salmon, 1980; Salmon and
Salmon, 1980). Cell viability and- cloning efficiency varied
depending on the individual tumour examined. All results are
expressed as colony survival relative to untreated controls.
Endotoxin controls were included when preparations of IL-1-
containing endotoxin were used. A tumour specimen was
regarded as being stimulated if the number of colonies in-
creased to more than 1.5 times control and as inhibited if the
number of colonies decreased to less than 0.5 times control
(Clark and Von Hoff, 1983).
Eighteen per cent of renal carcinomas were stimulated by
IL-la and thus were the most sensitive subgroup (Table I).
Similar data were obtained with IL-lp (data not shown). The
sensitivity of individual tumours was concentration depen-
dent and reached 1.83 times control (Figure 1). Inhibition of
clonogenic growth was observed in 4% of tumours without a
clear relationship to the IL-1 concentration used.
Data obtained with freshly explanted human tumour cells
were reproduced with established cell lines. Care was taken
to keep the passage number as low as possible (between 15
and 50) and relatively constant for each cell line. Of the four
cell lines used, two were from primary tumours (Caki-2 and
A498), one was from a skin metastasis of a renal carcinoma
(Caki-l) and one from a pleural effusion of a patient with
widely metastatic renal carcinoma (ACHN). All cell lines
were tested for endogenous production of IL-la and IL-lp
and were found not to release either cytokine into the
medium (data not shown).
Clonogenic growth of tumour cell lines from primary
cancers was stimulated in a concentration-dependent manner
by IL-la and IL-1p. With Caki-2 cells, stimulation was
observed in tissue culture medium containing 10% FCS and
reached 3.4 times control at 10 ng ml' IL-Ip and 2.5 times
control at 100 ng IL-la (Figure 2a). In contrast, A-498 cells
were only stimulated after serum deprivation (1% FCS) with
maximal effect of 2.0 times control at 100 ngml-' IL-Iac and
2.4 times control at 100 ngml1 IL-lp (Figure 2b). Two cell
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Table I Growth modulation offreshly explanted human tumours by increasing concentrations of interleukin la
0.1 1.0 10 100
Tumour type No. Stimulated Inhibited Stimulated Inhibited Stimulated Inhibited Stimulated Inhibited
Kidney 22 3 0 2 2 4 1 3 1
Colon 9 0 0 0 0 0 1 0 0
Stomach 2 0 0 0 0 0 0 0 0
Others 11 2 0 2 0 2 0 4 0
Total 44 5 0 4 2 6 2 7 1
Specimens were considered to be stimulated ifthe average colony formation was > 1.5 times control and to be inhibited ifthe
average colony fonnation was <0.5 times control (Clark and Von Hoff, 1983).IL1 modulatesgrowth of human renal carcinoma cells
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Figure 1 Representative concentration-response curves to IL-la
from two freshly explanted human renal carcinomas. Data repre-
sent mean and standard deviation of 4-6 assays.
lines from metastatic tumours (Caki-1, ACHN) failed to
react to IL-1.
The rate of cell division of A-498 and Caki-2 cells in the
absence or presence of IL-la or IL-1lB was determined by
[3H]thymidine incorporation and monolayer growth assays.
Concentrations of IL-Ia or IL-1Ip between 0.1 and 10 ngml1 l
were tested using various concentrations of serum (0.1%
BSA, 1% FCS, 10% FCS) and different incubation periods.
IL-la and IL-1p increased [3H]thymidine incorporation into
Caki-2 cells consistently and in a concentration-dependent
manner. With 10% FCS and lOngml[l IL-1p, stimulation
was maximal after 48 h (1.4 times control, Figure 3a),
whereas with 1% FCS maximal stimulation was reached only
after 72 h or later (1.4 times control, data not shown). Also,
monolayer growth was enhanced by IL-la and IL-1l up to
1.5 times control in 10% FCS (Figure 3b). In contrast, IL-1
decreased [H]thymidine incorporation into A-498 cells (0.5
times control at 10 ngml- IL-lot or IL-1IB, 1% FCS, Figure
3c). Similar results were obtained in a monolayer growth
experiment. After 72 h of incubation, cell numbers were 0.5
times control after incubation with 0.1 or 1Ong ml-' IL-1
(Figure 3d). As in soft-agar cloning experiments, IL-I
modulation of A-498 cell growth was only observed under
conditions of serum deprivation.
['25I1IL-1 receptor assays were performed with all four cell
lines to determine receptor number and binding affinity.
[1251lIL-la did not bind to Caki-I and ACHN cells (data not
shown). A498 cells were found to bind [(25lIL-la specifically
and in a saturable manner. Scatchard analysis indicated that
there are two classes of binding sites for IL-la on these cells:
high-affinity receptors (KD 4.5 x 10-11 M, 150-250 receptors
per cell) and low-affinity receptors (KD 1.3 x 10-9 M, 2500
receptors per cell) (Figure 4). Interestingly, no specific bind-
ing to Caki-2 cells was detectable with this technique.
In order to evaluate whether IL-1 could modulate its own
receptor, A-498 cells were incubated with increasing concen-
trations of IL-la for 48 h. Receptor binding of['25IlIL-l was
subsequently determined by incubation for 3 h at 4°C with
270 pM [125I]IL-la. Concentrations of more than 1 ngml-
IL-la were found to reduce [125I]IL-la binding by up to 50%
(Figure Sa). The influence of IL-la on ['25I]IL-la binding was
also time dependent: short periods (up to 30 min) of incuba-
tion with 2ngmlhl IL-la slightly enhanced IL-la binding,
whereas longer incubation periods reduced IL-la binding to
40% of control values (Figure Sb). Preliminary data from
Scatchard analyses of IL-1 radioreceptor assays with and
without IL-la preincubation indicate that reduced IL-la
binding after IL-la preincubation is due to reduced affinity
of the high-affinity receptors rather than to reduced receptor
numbers (data not shown).
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Figure 2 (a) Stimulation of clonogenic growth of Caki-2 human
renal carcinoma cells by IL-la and IL-1p (10% FCS). (b)
Stimulation of clonogenic growth of A-498 human renal car-
cinoma cells by IL-la and IL-1p (1% and 10% FCS). Data
represent mean and standard deviation of six assays.
We next attempted to characterise further IL-1 binding
sites on Caki-2 and A-498 cells as either IL-1 receptor type I
or type II. For this purpose, we performed soft-agar cloning
experiments with Caki-2 cells in the presence of 2 ng ml'
IL-1p and increasing concentrations of antibodies against
IL-1 receptor type I or type II. Antibodies alone were shown
not to influence clonogenic growth of the cells. Only
antibodies against IL-1 receptor type I inhibited IL-i-induced
stimulation of clonogenic growth, whereas antibodies against
IL-1 receptor type II had no effect on clonogenic prolifera-
tion (Figure 6). Signal transduction of IL-1 and Caki-2 cells
therefore appears to occur through receptor type I. Similar
results were obtained with A-498 cells (data not shown).
Next, we studied whether IL-1 receptor type I is the only
form of receptor species expressed by renal carcinoma cell
lines. Using immunoprecipitation techniques, we identified a
band of approximately 100 kDa in a subsequent Western blot
in A-498 cells, in which IL-I receptor type I (80 kDa) is
cross-linked to IL-1 (17 kDa) (Figure 7). To confirm the
identity of the receptor as type I we performed immunopre-
cipitations using anti-IL-i receptor type I or type II
antibodies directly to precipitate the receptor from fresh cell
lysates without prior cross-linking. In A-498 cells a signal
was observed using anti-IL-i receptor type I antibodies. No
signal was detected using anti-IL-i receptor type II
antibodies (data not shown). This indicates that binding of
IL-1 to A498 cells occurs via receptor type I. No receptors
were identified on Caki-2 cells, probably because the sen-
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Figure 3 (a) [3H]Thymidine incorporation into Caki-2 cells (10% FCS) under the influence of IL-IP. (b) Monolayer cell growth of
Caki-2 cells (10% FCS) under the influence of IL-la and IL-1p (10 ngml-1). (c) [3H]Thymidine incorporation into A-498 cells (1%
FCS) under the influence of IL-Ip. (d) Monolayer cell growth of A-498 cells (1% FCS) under the influence of IL-la and IL-lp
(1Ong ml').
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Figure 4 Scatchard analysis of ['"TI]IL-la receptor binding to A-498 renal cancer cells. Inserts show binding curves. (a) Direct
binding studies. (b) Competitive binding studies.
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Figure 6 Inhibition of IL-la-induced stimulation of clonogenic
growth of Caki-2 cells by monoclonal antibodies to IL-1 receptor
type I and II. Data represent mean and standard deviation of six
assays.
A B
190 -
120 -
88 -
70 -
56 -
Time of preincubation (h)
Figure 5 (a) Ligand-induced down-regulation of['251I]IL-la bind-
ing to A-498 cells after preincubation with IL-la for 48 h. (b)
Influence of preincubation time of IL-la (2 ngml') on ['25I]IL-
la binding.
sitivity of the available methods is insufficient to identify
these weakly expressed molecules.
Discussion
Though primarily identified as a haematopoietic growth fac-
tor, IL-I now has to be regarded as a peptide with growth-
modulating effects on many cell types, including human
tumour cells. At present, it is not known whether growth
stimulation or inhibition of tumour cells influences tumour
biology in vivo. However, the beneficial effects of IL-I on
haematopoiesis may be used to decrease myelotoxic effects
induced by cytotoxic chemotherapy.
In vitro, cloning of freshly explanted human tumour cells
has demonstrated that exposure to IL-I may modulate
clonogenic growth in a subset of tumours. In confirmation of
earlier results from our group, most stimulated tumours were
renal carcinomas (Donne et al., 1992). Since it is largely
accepted that tumour cell lines are a good in vitro model for
mechanistic investigations, renal carcinoma cell lines were
used for further studies, bearing in mind that some changes
may have occurred during in vitro passaging. In agreement
with our results from clinical tumour specimens, the
clonogenicity of two out of four human renal carcinoma cell
lines increased under the influence ofIL-1. Interestingly, both
responsive cell lines (Caki-2 and A-498) had been established
from primary tumours, while two cell lines from metastatic
Figure 7 Immunoprecipitation of IL-I receptor type I after
cross-linking to IL-la, detected by a monoclonal antibody to
IL-la. Size markers are given in kDa. Lane A, Caki-2 cells; lane
B, A-498 cells. Arrows indicate immunoprecipitated IL-1 receptor
type I cross-linked to IL-la (100 kDa), IgGI antibody to IL-la
(48 kDa) and IL-la (17 kDa).
lesions lacked IL-1 sensitivity in clonogenic growth experi-
ments. For Caki-2, cell proliferation as determined by
monolayer growth and [3H]thymidine uptake was also
enhanced. In contrast, A-498 cells showed a decrease in
overall [3H]thymidine incorporation and monolayer prolifera-
tion. This indicates that IL-1 may differentially act on cells
that retain clonogenic capabilities.
In a next step we found A-498 cells to bind IL-I in a
saturable manner. Scatchard analysis of the binding data
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revealed high-affinity receptors with low density and low-
affinity binding sites with higher density. The number of IL-1
receptors per cell and their dissociation constants are in the
range of those published for other human tumour cell lines,
although other investigators only reported on a single class
of receptors. Breast cancer cells (MCF-7) express 2500 IL-1
receptors per cell with a KD of 200pM (Paciotti and Tamar-
kin, 1988). The human ovarian carcinoma cell line Ovcar-3
has been reported to express 7800 sites per cell with a KD of
55 pM (Tsai and Gaffney, 1987). Lower receptor numbers
have been found on NIM-1 human thyroid carcinoma cells
(664 molecules per cell, KD 110pM) as well as in MDA-MB-
415 breast cancer cells (700 per cell, KD 880 pM) (Gaffney et
al., 1988; Zeki et al., 1993). Although Caki-2 cells were more
sensitive to the proliferative effects of IL-1, cell-surface recep-
tors could not be identified using [1251]IL-1. The reasons for
this are unclear but may be related to low receptor numbers
on these cells and sensitivity limits of the assays used.
In order to characterise further the functional status of
IL-1 receptors on A-498 cells, we performed binding
experiments after preincubation with unlabelled ligand. We
found that IL-la reduced binding of ['251]IL-bx to its recep-
tor. The concentration of unlabelled ligand was saturating at
least for the high-affinity binding sites. These data are in
accordance with published reports that saturating concentra-
tions of IL-la or IL-lp down-regulate cell-surface expression
of IL-1 receptor by destabilising its mRNA (Ye et al., 1992).
However, Scatchard analyses clearly indicate that reduced
binding to A498 cells is not due to reduced receptor number,
but rather to reduced receptor affinity. In this context it may
be interesting to note that receptor number might have little
or no influence on the extent of the biological response, since
a receptor occupancy of 1-100 molecules per cell has been
reported to be sufficient for efficient signal transduction
(Dower et al., 1985). However, reduced affinity of high-
affinity receptors may well weaken the biological signal, par-
ticularly at low concentrations of ligand.
While 250 high-affinity receptors on A-498 cells are
sufficient for effective signal transduction, a far lower recep-
tor number, which is too low for identification by radiorecep-
tor assays, may account for IL-i-induced growth stimulation
of Caki-2 cells.
From our experiments, we cannot exclude the possibility
that Caki-I and ACHN cells also express a small number of
cell-surface receptors. However, if this is the case, binding of
IL-1 to its receptor does not change the growth behaviour of
these cells.
Early reports have postulated that both type I and type II
IL-1 receptors are functional in ligand binding and capable
of signal transduction. However, recent reports support the
notion that only receptor type I can mediate IL-1-induced
biological effects, at least in lymphocytes (Sims et al., 1993).
While the intracellular domain of this molecule with 217
amino acids is large enough for a yet unidentified enzymatic
function, the intracellular domain of receptor type II is too
short. Binding of IL-1 to receptor type II may reduce the
effective IL-1 concentration and thus may have a regulatory
function with regard to biological effects (Colotta et al.,
1993). In Caki-2 and A-498 cells, IL-i-induced stimulation of
clonogenic growth was prevented by antibodies to receptor
type I but not to receptor type II. This indicates that IL-1
signal transduction in these cells is also conferred via this
receptor type. Similarly, binding of IL-1 to A-498 cells was
inhibited by 50% by antibodies to receptor type I at the
concentrations of antibody used. We therefore conclude that
renal cancer cells mainly express IL-1 receptor type I. Inhibi-
tion of IL-1 binding by 25% by antibody to receptor type II
may be explained by a lack of specificity of the antibodies
used.
In confirmation of cell biological data, a single band of
about 100 kDa was immunoprecipitated by antibodies to
IL-l( after cross-linking of IL-lx to A-498 cells. The size of
this band corresponds to IL-I receptor type I (80 kDa) cross-
linked to IL-I (17 kDa). No band of minor size which might
represent IL-I receptor type 11 (60 kDa) was identified. We
therefore hypothesise that binding of IL-1 to renal carcinoma
cells occurs via IL-1 receptor type I and that this receptor is
also responsible for signal transduction. Similar results have
been obtained with MCF-7 cells, indicating a general role for
receptor type I in IL-1 signal transduction not only in lym-
phocytes but also in cancer cells (Paciotti and Tamarkin,
1988).
In summary, our data indicate that IL-1 can modulate
growth of human renal cancer cells and that this effect is
conferred by IL-1 receptor type I.
Abbrevations DSS, disuccinimidylsuberate; HEPES, 4-(2-hydroxy-
ethyl)-l-piperazineethanesulphonic acid; SDS, sodium docecyl sul-
phate; FCS, fetal calf serum; BSA, bovine serum albumin; ELISA,
enzyme-linked immunosorbent assay.
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